(Q42476947)

1 November 2017

title

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

1 November 2017

main subject

1 reference

1 reference

1 reference

1 reference

steroid biosynthetic process

1 reference

Unlühizarci K

1

1 reference

1 November 2017

Keleştimur F

2

1 reference

1 November 2017

Bayram F

3

1 reference

1 November 2017

Sahin Y

4

1 reference

1 November 2017

Tutuş A

5

1 reference

1 November 2017

publication date

1 August 1999

1 reference

1 November 2017

published in

Clinical Endocrinology

1 reference

1 November 2017

volume

51

1 reference

1 November 2017

issue

2

1 reference

1 November 2017

page(s)

231-236

1 reference

Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

The polycystic ovary syndrome: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Insulin resistance in nonobese patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00786.X

10.1046/J.1365-2265.1999.00786.X

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference